Lisdexamfetamine Dimesylate Capsule
Product Images NDC 0406-5112

16 FDA label images from Specgx Llc · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Lisdexamfetamine Dimesylate (NDC 0406-5112). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Specgx Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Lisdexamfetamine Caps 1)

Chemical Structure (Lisdexamfetamine Caps 1)
Chemical structure of Lisdexamfetamine Dimesylate, showing the molecular arrangement of atoms including benzene ring, amide group, and two mesylate groups.*
FDA Label Image

Figure 1 (Lisdexamfetamine Caps 2)

Figure 1 (Lisdexamfetamine Caps 2)
A forest plot chart illustrating the fold change and 90% confidence intervals in pharmacokinetic parameters Cmax and AUC for lisdexamfetamine dimesylate across special populations, including gender, age groups (65-74 years, ≥75 years), and varying degrees of renal impairment from mild to end stage renal disease. The horizontal axis shows the change relative to reference values.*
FDA Label Image

Figure 2 (Lisdexamfetamine Caps 3)

Figure 2 (Lisdexamfetamine Caps 3)
A forest plot chart showing the fold change and 90% confidence intervals for pharmacokinetic parameters Cmax and AUC of three drugs (Guanfacine, Venlafaxine, Omeprazole) relative to a reference. The x-axis represents the change relative to reference, ranging from 0.0 to 2.0, with data points clustered near 1.0 indicating minimal change.*
FDA Label Image

Figure 3 (Lisdexamfetamine Caps 4)

Figure 3 (Lisdexamfetamine Caps 4)
A forest plot chart illustrating the pharmacokinetic (PK) fold changes and 90% confidence intervals (CI) for various interacting drugs with Lisdexamfetamine Dimesylate. The chart compares Cmax and AUC values for drugs including Guanfacine, Venlafaxine, CYP1A2 substrate caffeine, CYP2D6 substrate dextromethorphan, CYP2C19 substrate omeprazole, and CYP3A substrate midazolam, relative to a reference.*
FDA Label Image

Figure 4 (Lisdexamfetamine Caps 5)

Figure 4 (Lisdexamfetamine Caps 5)
Line graph comparing LS mean (SE) SKAMP Deportment Scores over time post-dose for Lisdexamfetamine Dimesylate Capsules versus placebo. The x-axis shows time post-dose in hours from -0.5 to 13, and the y-axis shows score values from 0.0 to 2.0. The graph shows two curves, one solid line for Lisdexamfetamine Dimesylate Capsules and one dashed line for placebo, with error bars for standard error.*
FDA Label Image

Figure 5-1 (Lisdexamfetamine Caps 6)

Figure 5-1 (Lisdexamfetamine Caps 6)
A survival curve chart comparing Lisdexamfetamine Dimesylate Capsules and placebo over time in days after randomization. The y-axis shows the proportion of subjects with relapse or treatment failure as a percentage, and the x-axis represents days from 0 to 55. The curve indicates fewer relapses/treatment failures with Lisdexamfetamine Dimesylate Capsules versus placebo across the time period.*
FDA Label Image

Figure 6 (Lisdexamfetamine Caps 7)

Figure 6 (Lisdexamfetamine Caps 7)
A line graph showing LS Mean (SE) PERMP Total Scores over time post-dose (hours) comparing Lisdexamfetamine Dimesylate Capsules and placebo. The x-axis represents time from -0.5 to 14 hours post-dose, and the y-axis shows scores from 250 to 330. Two lines illustrate that scores for Lisdexamfetamine Dimesylate Capsules consistently exceed those of placebo across the time points, with error bars indicating standard error.*
FDA Label Image

Figure 7 (Lisdexamfetamine Caps 8)

Figure 7 (Lisdexamfetamine Caps 8)
A line graph comparing the proportion of subjects with relapse or treatment failure over time between Lisdexamfetamine Dimesylate Capsules and placebo. The x-axis shows time in days after randomization (0 to 40 days), and the y-axis shows the proportion of subjects with relapse or treatment failure as a percentage (0% to 100%). The solid line represents Lisdexamfetamine Dimesylate Capsules, which shows a consistently low rate, while the dashed line represents placebo, which shows a progressively increasing rate over time.*
FDA Label Image

Figure 8 (Lisdexamfetamine Caps 9)

Figure 8 (Lisdexamfetamine Caps 9)
A Kaplan-Meier survival curve comparing the proportion of subjects with relapse over time between Lisdexamfetamine Dimesylate capsules and placebo groups. The chart shows days after randomization on the x-axis and percentage of subjects with relapse on the y-axis. Subject counts at risk for both groups are listed below the x-axis at various time points.*
FDA Label Image

Principal Display Panel (10 mg Capsules)

Principal Display Panel (10 mg Capsules)
Label for Lisdexamfetamine Dimesylate 10 mg capsules, packaged as 100 capsules. The label includes the NDC code 0406-5111-01 and instructions for pharmacists to dispense the Medication Guide. Storage instructions recommend room temperature between 20°C to 25°C with excursion limits. The manufacturer is SpecGx LLC, Webster Groves, MO, USA.*
FDA Label Image

Principal Display Panel (20 mg Capsules)

Principal Display Panel (20 mg Capsules)
Lisdexamfetamine Dimesylate 20 mg capsules label showing a package of 100 capsules. The label includes the NDC number 0406-5112-01, instructions for pharmacists to dispense the Medication Guide, storage conditions, and manufacturing information by SpecGx LLC, Webster Groves, MO. The label states Rx only and highlights the active ingredient strength.*
FDA Label Image

Principal Display Panel (30 mg Capsules)

Principal Display Panel (30 mg Capsules)
Label for Lisdexamfetamine Dimesylate 30 mg capsules, containing 100 capsules per bottle. The label includes NDC 0406-5113-01 and states the capsules are for oral use, prescription only (Rx only). Manufactured for SpecGx LLC, Webster Groves, MO. Instructions on pharmacist dispensing and storage conditions are also present on the label.*
FDA Label Image

Principal Display Panel (40 mg Capsules)

Principal Display Panel (40 mg Capsules)
Label for Lisdexamfetamine Dimesylate Capsules 40 mg, containing 100 capsules. The label includes dosage strength, a schedule II controlled substance symbol, and instructions for pharmacists to dispense the medication guide. Storage instructions specify room temperature with permitted excursion ranges. Manufactured for SpecGx LLC, Webster Groves, MO, USA.*
FDA Label Image

Principal Display Panel (50 mg Capsules)

Principal Display Panel (50 mg Capsules)
Label of Lisdexamfetamine Dimesylate 50 mg capsules, package containing 100 capsules, manufactured for SpecGx LLC. The label includes the NDC 0406-5115-01 and notes pharmacist instructions, dosage form as oral capsules, and storage conditions at room temperature. The label emphasizes the need to dispense the Medication Guide separately.*
FDA Label Image

Principal Display Panel (60 mg Capsules)

Principal Display Panel (60 mg Capsules)
Label for Lisdexamfetamine Dimesylate 60 mg capsules manufactured for SpecGx LLC. The label indicates a package containing 100 capsules, includes storage instructions, and states the drug is a Schedule II controlled substance, Rx only, with pharmacist instructions to dispense the Medication Guide separately.*
FDA Label Image

Principal Display Panel (70 mg Capsules)

Principal Display Panel (70 mg Capsules)
Label for Lisdexamfetamine Dimesylate 70 mg capsules, packaged as 100 capsules per bottle. The label includes the NDC 0406-5117-01 and instructs pharmacists to dispense the medication guide separately. It states storage instructions to keep at room temperature and in a light-resistant container. Manufactured for SpecGx LLC, Webster Groves, MO.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.